Alain H. Rook

faculty photo
Professor of Dermatology
Department: Dermatology

Contact information
Department of Dermatology
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
Philadelphia, Pa. 19104
Philadelphia, PA 19104
Office: 215-662-7610
Fax: 215-349-8173
Education:
B.A. (Biology)
Brandeis University, 1971.
M.D. (Medicine)
University of Michigan, 1975.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, Haun PL, Vittorio CC, Rook AH, Kim EJ, Samimi SS.: Usage and safety of topical tacrolimus in patients with mycosis fungoides. Clin Exp Dermatol. March 2022 Notes: doi: 10.1111/ced.15162. Online ahead of print.PMID: 35245947.

Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS.: Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol. J Invest Dermatol. 142(2): 493-496, February 2022 Notes: doi: 10.1016/j.jid.2021.06.034. Epub 2021 Aug 3.PMID: 34358529 No abstract available.

Lewis DJ, Rook AH.: Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations. Int J Dermatol. 60(9): e362-e364, September 2021 Notes: doi: 10.1111/ijd.15436. Epub 2021 Feb 9.PMID: 33559132 No abstract available.

Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ.: Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. JAMA Dermatol. 157(3): 317-321, March 2021 Notes: doi: 10.1001/jamadermatol.2020.4901.PMID: 33377934 Free PMC article.

Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158(1): 1-7, March 2015.

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC: Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma (20), 1-22, March 2015.

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.: Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 20: 1-22, March 2015.

Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.: Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 17(2): 78-84, May-August 2014.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.: CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. J Invest Dermatol 134: 229-36, 2014.

Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ.: Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149(5), May 2013.

back to top
Last updated: 09/01/2022
The Trustees of the University of Pennsylvania